Integration of Urinary EN2 Protein & Cell-Free RNA Data in the Development of a Multivariable Risk Model for the Detection of Prostate Cancer Prior to Biopsy.
TRIPOD
biomarker
liquid biopsy
machine learning
prostate cancer
urine
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
27 Apr 2021
27 Apr 2021
Historique:
received:
15
02
2021
revised:
13
04
2021
accepted:
14
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
The objective is to develop a multivariable risk model for the non-invasive detection of prostate cancer prior to biopsy by integrating information from clinically available parameters, Engrailed-2 (EN2) whole-urine protein levels and data from urinary cell-free RNA. Post-digital-rectal examination urine samples collected as part of the Movember Global Action Plan 1 study which has been analysed for both cell-free-RNA and EN2 protein levels were chosen to be integrated with clinical parameters (
Identifiants
pubmed: 33925381
pii: cancers13092102
doi: 10.3390/cancers13092102
pmc: PMC8123800
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Movember Foundation
ID : GAP1 Urine Biomarker project
Organisme : Masonic Charitable Foundation
ID : Cooper
Organisme : The Bob Champion Cancer Trust
ID : Cooper
Organisme : the King family
ID : Cooper
Organisme : The Andy Ripley Memorial Fund
ID : Cooper
Organisme : Stephen Hargrave Trust
ID : Cooper
Références
JAMA Oncol. 2016 Jul 1;2(7):882-9
pubmed: 27032035
Lancet Oncol. 2014 Sep;15(10):1109-18
pubmed: 25163905
BJU Int. 2019 May 20;:
pubmed: 31106513
BMC Med. 2016 Apr 04;14:67
pubmed: 27044421
Oncotarget. 2016 Jun 14;7(24):35818-35831
pubmed: 27127882
Clin Epigenetics. 2018 Nov 23;10(1):147
pubmed: 30470249
Eur Urol Focus. 2018 Dec;4(6):842-850
pubmed: 28753852
Eur Urol. 2018 Jan;73(1):31-32
pubmed: 28965689
Contemp Oncol (Pozn). 2015;19(6):471-3
pubmed: 26843845
JAMA. 2018 Mar 6;319(9):883-895
pubmed: 29509864
Cancer Treat Rev. 2017 Mar;54:68-73
pubmed: 28231559
Nat Rev Urol. 2016 Apr;13(4):205-15
pubmed: 26954332
Eur Urol. 2017 Apr;71(4):630-642
pubmed: 27591931
Eur Urol. 2015 Feb;67(2):326-33
pubmed: 24998118
Eur Urol. 2014 Jun;65(6):1046-55
pubmed: 24439788
Lancet. 2017 Feb 25;389(10071):815-822
pubmed: 28110982
Eur Urol. 2003 Jul;44(1):8-15; discussion 15-6
pubmed: 12814669
BJU Int. 2012 Sep;110(6 Pt B):E287-92
pubmed: 22583908
BMC Genomics. 2013 Oct 08;14:690
pubmed: 24103217
Med Decis Making. 2006 Nov-Dec;26(6):565-74
pubmed: 17099194
Eur Urol. 2015 Jun;67(6):1142-1151
pubmed: 25572824
J Urol. 2019 Aug;202(2):256-263
pubmed: 31026217
Int J Cancer. 2019 Dec 15;145(12):3445-3452
pubmed: 31125115
Prostate. 2020 May;80(7):547-558
pubmed: 32153047
Front Oncol. 2020 Jan 09;9:1484
pubmed: 31993369
Eur Urol Focus. 2019 Jul;5(4):592-599
pubmed: 29226826
Br J Cancer. 2012 Mar 13;106(6):1095-9
pubmed: 22361632
J Clin Oncol. 2009 Jul 20;27(21):3459-64
pubmed: 19433685
Eur Urol. 2016 Jul;70(1):45-53
pubmed: 25985884
BMC Bioinformatics. 2011 Mar 17;12:77
pubmed: 21414208
BMC Med Genomics. 2015 Aug 22;8:54
pubmed: 26297356
Nat Methods. 2019 Jul;16(7):565-566
pubmed: 31217592
J Urol. 2018 Mar;199(3):683-690
pubmed: 29203269
Sci Rep. 2019 Mar 26;9(1):5138
pubmed: 30914795
FEBS Lett. 2006 May 15;580(11):2531-3
pubmed: 16674951
Eur Urol. 2016 Nov;70(5):740-748
pubmed: 27108162
JCO Precis Oncol. 2019;2019:
pubmed: 30801051
Infection. 1991;19 Suppl 3:S115-8
pubmed: 2055645
Eur Urol Focus. 2018 Sep;4(5):707-710
pubmed: 28753803
Br J Cancer. 2020 May;122(10):1467-1476
pubmed: 32203215
Sci Rep. 2013;3:2059
pubmed: 23792811
Biotechniques. 2020 Feb;68(2):65-71
pubmed: 31779479
J Clin Oncol. 2016 Jul 20;34(21):2534-40
pubmed: 27247223
Clin Cancer Res. 2011 Mar 1;17(5):1090-8
pubmed: 21364037